FAQ on BriaCell Therapeutics Corp.'s $13.8 Million Public Offering
Summary
What is the purpose of BriaCell Therapeutics Corp.’s public offering?
The public offering aims to raise approximately $13.8 million for working capital, corporate purposes, and advancing the company’s business objectives.
How much is BriaCell Therapeutics Corp. offering per unit and what does each unit include?
Each unit is priced at $4.50 and includes one common share or pre-funded warrant and one warrant exercisable at $5.25 per share.
When is BriaCell Therapeutics Corp.’s public offering expected to close?
The offering is expected to close on April 28, 2025, subject to customary closing conditions.
Who is leading BriaCell Therapeutics Corp.’s public offering?
ThinkEquity is leading the underwritten public offering.
Where can I find more information about BriaCell Therapeutics Corp.?
For more information, visit the company’s website at https://briacell.com/.
What does BriaCell Therapeutics Corp. specialize in?
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Where can I view the full article about BriaCell Therapeutics Corp.’s public offering?
The full article can be viewed at https://ibn.fm/745T0.
What are the terms of use and disclaimers for the content provided by InvestorWire?
The terms of use and disclaimers can be found on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118941